The Red Menace: Emerging Issues in Antimicrobial Resistance in Gram-Negative Bacilli
- PMID: 11095807
- DOI: 10.1007/s11908-999-0040-4
The Red Menace: Emerging Issues in Antimicrobial Resistance in Gram-Negative Bacilli
Abstract
Gram-negative bacilli cause more than one third of all nosocomial infections in US hospitals. Despite a surfeit of new and highly potent antimicrobial agents, the problem of resistance in these pathogens continues to increase. Particularly important is the emergence of resistance to the fluoroquinolone and beta-lactam classes of antimicrobial agents. Recent work has confirmed that resistance to fluoroquinolone antibiotics is a complex process that involves mutations in the target enzymes (topoisomerase II and IV), decreased access to the target enzyme resulting from low permeability of the outer membrane (this is primarily important in Pseudomonas aeruginosa), and active efflux from the cell. Resistance to beta-lactam antibiotics, however, is primarily caused by the elaboration of an ever-growing number of beta-lactamases. Our ability to understand the genetic and biochemical underpinnings of these resistance phenotypes will be an important factor in determining the ultimate success of efforts to control their emergence and spread.
Similar articles
-
Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli.Am J Med. 1997 Jul;103(1):51-9. doi: 10.1016/s0002-9343(97)00044-2. Am J Med. 1997. PMID: 9236486 Review.
-
Emerging issues in the management of infections caused by multi-drug-resistant, gram-negative bacilli.Surg Infect (Larchmt). 2005;6 Suppl 2:S-37-47. Surg Infect (Larchmt). 2005. PMID: 23577496 Review.
-
Pseudomonas aeruginosa - a phenomenon of bacterial resistance.J Med Microbiol. 2009 Sep;58(Pt 9):1133-1148. doi: 10.1099/jmm.0.009142-0. Epub 2009 Jun 15. J Med Microbiol. 2009. PMID: 19528173 Review.
-
[Multiresistant Gram-negative bacterial infections: Enterobacteria, Pseudomonas aeruginosa, Acinetobacter baumannii and other non-fermenting Gram-negative bacilli].Enferm Infecc Microbiol Clin. 2013 Jun-Jul;31(6):402-9. doi: 10.1016/j.eimc.2013.03.016. Epub 2013 May 17. Enferm Infecc Microbiol Clin. 2013. PMID: 23684390 Review. Spanish.
-
Tigecycline: in-vitro performance as a predictor of clinical efficacy.Clin Microbiol Infect. 2007 Apr;13(4):354-62. doi: 10.1111/j.1469-0691.2006.01621.x. Clin Microbiol Infect. 2007. PMID: 17359318 Review.
References
LinkOut - more resources
Full Text Sources